Patents by Inventor Klaas Poelstra
Klaas Poelstra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190389923Abstract: The invention relates to the field of medicine. Among others, it relates to biologically active analogs of interferons (IFNs) which show less unwanted side-effects and to the therapeutic uses thereof. Provided is an IFN analog, wherein the moiety mediating binding to its natural receptor is at least functionally disrupted and wherein the analog comprises a signaling moiety capable of mediating intracellular IFN activity, said signaling moiety being provided at its N-terminus, optionally via a linker, with at least one targeting domain capable of binding to a cell surface receptor other than the IFN receptor.Type: ApplicationFiled: September 9, 2019Publication date: December 26, 2019Inventors: Klaas Poelstra, Jai Prakash, Eleonora Beljaars, Ruchi Bansal
-
Patent number: 10442845Abstract: The invention relates to the field of medicine. Among others, it relates to biologically active analogs of interferons (IFNs) which show less unwanted side-effects and to the therapeutic uses thereof. Provided is an IFN analog, wherein the moiety mediating binding to its natural receptor is at least functionally disrupted and wherein the analog comprises a signaling moiety capable of mediating intracellular IFN activity, said signaling moiety being provided at its N-terminus, optionally via a linker, with at least one targeting domain capable of binding to a cell surface receptor other than the IFN receptor.Type: GrantFiled: April 11, 2018Date of Patent: October 15, 2019Assignee: BiOrion Technologies B.V.Inventors: Klaas Poelstra, Jai Prakash, Eleonora Beljaars, Ruchi Bansal
-
Publication number: 20180298075Abstract: The invention relates to the field of medicine. Among others, it relates to biologically active analogs of interferons (IFNs) which show less unwanted side-effects and to the therapeutic uses thereof. Provided is an IFN analog, wherein the moiety mediating binding to its natural receptor is at least functionally disrupted and wherein the analog comprises a signaling moiety capable of mediating intracellular IFN activity, said signaling moiety being provided at its N-terminus, optionally via a linker, with at least one targeting domain capable of binding to a cell surface receptor other than the IFN receptor.Type: ApplicationFiled: April 11, 2018Publication date: October 18, 2018Inventors: Klaas Poelstra, Jai Prakash, Eleonora Beljaars, Ruchi Bansal
-
Publication number: 20160297861Abstract: The invention relates to the field of medicine. Among others, it relates to biologically active analogs of interferons (IFNs) which show less unwanted side-effects and to the therapeutic uses thereof. Provided is an IFN analog, wherein the moiety mediating binding to its natural receptor is at least functionally disrupted and wherein the analog comprises a signaling moiety capable of mediating intracellular IFN activity, said signaling moiety being provided at its N-terminus, optionally via a linker, with at least one targeting domain capable of binding to a cell surface receptor other than the IFN receptor.Type: ApplicationFiled: June 9, 2016Publication date: October 13, 2016Inventors: Klaas Poelstra, Jai Prakash, Eleonora Beljaars, Ruchi Bansal
-
Patent number: 9381230Abstract: The invention relates to the field of medicine. Among others, it relates to biologically active analogs of interferons (IFNs) which show less unwanted side-effects and to the therapeutic uses thereof. Provided is an IFN analog, wherein the moiety mediating binding to its natural receptor is at least functionally disrupted and wherein the analog comprises a signaling moiety capable of mediating intracellular IFN activity, said signaling moiety being provided at its N-terminus, optionally via a linker, with at least one targeting domain capable of binding to a cell surface receptor other than the IFN receptor.Type: GrantFiled: December 30, 2010Date of Patent: July 5, 2016Assignee: BiOrion Technologies, B.V.Inventors: Klaas Poelstra, Jai Prakash, Eleonora Beljaars, Ruchi Bansal
-
Patent number: 8735087Abstract: The present invention provides a use for alkaline phosphatase for the manufacture of a medicament for the prevention or reduction of toxic LPS influx through a mucosal lining of a mammalian body cavity. A source of alkaline phosphatase is administered for the prophylaxis or treatment of LPS mediated or exacerbated diseases. The invention also provides compositions comprising a source of alkaline phosphatase for the prevention or reduction of (toxic) LPS influx or passage through mucosal layers.Type: GrantFiled: February 15, 2013Date of Patent: May 27, 2014Assignee: PharmAAware Sepsis B.V.Inventors: Rudi Brands, Klaas Poelstra
-
Patent number: 8574863Abstract: The present invention provides a use for alkaline phosphatase for the manufacture of a medicament for the prevention or reduction of toxic LPS influx through a mucosal lining of a mammalian body cavity. A source of alkaline phosphatase is administered for the prophylaxis or treatment of LPS mediated or exacerbated diseases. The invention also provides compositions comprising a source of alkaline phosphatase for the prevention or reduction of (toxic) LPS influx or passage through mucosal layers.Type: GrantFiled: February 4, 2005Date of Patent: November 5, 2013Assignee: PharmAAware Sepsis B.V.Inventors: Rudi Brands, Klaas Poelstra
-
Publication number: 20130064791Abstract: The invention relates to the field of medicine. Among others, it relates to biologically active analogs of interferons (IFNs) which show less unwanted side-effects and to the therapeutic uses thereof. Provided is an IFN analog, wherein the moiety mediating binding to its natural receptor is at least functionally disrupted and wherein the analog comprises a signaling moiety capable of mediating intracellular IFN activity, said signaling moiety being provided at its N-terminus, optionally via a linker, with at least one targeting domain capable of binding to a cell surface receptor other than the IFN receptor.Type: ApplicationFiled: December 30, 2010Publication date: March 14, 2013Applicant: BIORION TECHNOLOGIES B.V.Inventors: Klaas Poelstra, Jai Prakash, Eleonora Beljaars, Ruchi Bansal
-
Publication number: 20110142817Abstract: Compositions comprising a source of alkaline phosphatase that prevent or reduce toxic influx of lipopolysaccharide (LPS) through mucosal layers of a mamalian body cavity and methods of using these compositions for those purposes are disclosed. Such a source of alkaline phosphatase, preferably in a medical food such as infant milk formula, is eaten, drunk or otherwise administered for prophylaxis or treatment of LPS-mediated or LPS-exacerbated disease.Type: ApplicationFiled: July 6, 2010Publication date: June 16, 2011Applicant: PHARMAAWARE SEPSIS B.V.Inventors: Rudi BRANDS, Klaas Poelstra
-
Publication number: 20110104103Abstract: The present invention relates to a cell-targeting complex comprising a targeting moiety and a deliverable compound, wherein said targeting moiety and said deliverable compound are joined by means of a (transition) metal ion complex having at least a first reactive moiety for forming a coordination bond with a reactive site of said targeting moiety and having at least a second reactive moiety for forming a coordination bond with a reactive site of said deliverable compound, and wherein said deliverable compound is a therapeutic compound.Type: ApplicationFiled: July 20, 2006Publication date: May 5, 2011Applicant: KREATECH BIOTECHNOLOGY B.V.Inventors: Robert Jochem Heetebrij, Robbert Jan Kok, Eduard Gerhard Talman, Klaas Poelstra, Grietje Molema
-
Publication number: 20090010912Abstract: The present invention provides a use for alkaline phosphatase for the manufacture of a medicament for the prevention or reduction of toxic LPS influx through a mucosal lining of a mammalian body cavity. A source of alkaline phosphatase is administered for the prophylaxis or treatment of LPS mediated or exacerbated diseases. The invention also provides compositions comprising a source of alkaline phosphatase for the prevention or reduction of (toxic) LPS influx or passage through mucosal layers.Type: ApplicationFiled: February 4, 2005Publication date: January 8, 2009Applicant: PHARMAAWARE SEPSIS B.V.Inventors: Rudi Brands, Klaas Poelstra
-
Publication number: 20080267877Abstract: A compound includes a carrier molecule wherein the carrier molecule is linked to a further molecule, wherein the further molecule is at least one cyclic peptide in which the cyclic peptide portion thereof contains at least one sequence encoding a cell receptor recognizing peptide (RRP) and with the proviso that the compound is not a naturally occurring receptor agonist or antagonist. Preferably, the RRP is a receptor specific for Hepatic Stellate Cells (HSC) or a receptor that is up-regulated on HSC during disease. The RFP may be chosen from among a PDGF receptor, a collagen type VI receptor, cytokine receptor(s) such as TGB?, INF? and interleukin?. The cyclic portion of the peptide can contain at least one amino acid sequence RGD or KPT.Type: ApplicationFiled: March 24, 2008Publication date: October 30, 2008Applicants: Stichting voor de Technische Wetenschappen, Rijksuniversiteit GroningenInventors: Klaas Poelstra, Eleonora Beljaars, Dirk Klaas Fokke Meijer, Detlef Bruno Igor Schuppan
-
Publication number: 20050227916Abstract: A compound includes a carrier molecule wherein the carrier molecule is linked to a further molecule, wherein the further molecule is at least one cyclic peptide in which the cyclic peptide portion thereof contains at least one sequence encoding a cell receptor recognizing peptide (RRP) and with the proviso that the compound is not a naturally occurring receptor agonist or antagonist. Preferably, the RRP is a receptor specific for Hepatic Stellate Cells (HSC) or a receptor that is up-regulated on HSC during disease. The RFP may be chosen from among a PDGF receptor, a collagen type VI receptor, cytokine receptor(s) such as TGB?, INF? and interleukin?. The cyclic portion of the peptide can contain at least one amino acid sequence RGD or KPT.Type: ApplicationFiled: December 15, 2004Publication date: October 13, 2005Applicants: Stichting voor de Technische Wetenschappen, Rijksuniversiteit GroningenInventors: Klaas Poelstra, Eleonora Beljaars, Dirk Meijer, Detlef Schuppan
-
Patent number: 6844319Abstract: The present invention relates to a compound comprising a carrier molecule, said carrier molecule being linked to a further molecule, said further molecule being at least one cyclic peptide, said cyclic peptide comprising in the cyclic peptide portion thereof at least one sequence encoding a cell receptor recognising peptide (RRP) and with the proviso that the compound is not a naturally occuring receptor agonist or antagonist. Preferably, the RRP is of a receptor specific for Hepatic Stellate Cells (HSC) or a receptor that is upregulated on HSC during disease. In particular, the RRP may be of a receptor selected from the group of PDGF receptor, collagen type VI receptor, cytokine receptor(s) such as TGF?, IFN? and interleukin 1?. Preferably, the cyclic portion of the cyclic peptide comprises at least the amino acid sequence RGD or KPT.Type: GrantFiled: October 8, 1998Date of Patent: January 18, 2005Assignees: Stichting voor de Technische Wetenschappen, Rijksuniversiteit GroningenInventors: Klaas Poelstra, Eleonora Beljaars, Dirk Klaas Fokke Meijer, Detlef Bruno Igor Schuppan
-
Patent number: 6290952Abstract: The invention relates to pharmaceutical compositions suitable for treating or curing clinical complications mediated by endotoxin, including sepsis. The compositions contain components suitable for detoxifying endotoxin rendering it less deleterious to mammals such as humans, in particular to patients with reduced host-defence resistance. The invention also relates to pharmaceutical compositions suitable for stimulating bone formation, e.g. for mending broken bone or for prophylaxis or therapy of metabolic bone diseases such as osteoporosis and osteomalacia and pharmaceutical compositions for decreasing or inhibiting undesired bone formation. The pharmaceutical compositions according to the invention are directed at modulating phosphatase activity in vivo.Type: GrantFiled: April 10, 1996Date of Patent: September 18, 2001Assignee: Rijksuniversiteit GroningenInventors: Klaas Poelstra, Machiel Josephus Hardonk, Winston Willem Bakker, Dirk KLaas Fokke Meijer